Congestive Heart Failure Treatment Devices Market Analysis

The congestive heart failure treatment devices market by product is categorized into defibrillators, pacemakers, cardiac resynchronization therapy devices, ventricular assist devices (VADs), and other products. The defibrillators segment accounted for 52.6% market share in 2023 and is anticipated to witness significant growth during the forecast period.­

• Defibrillators are critical in preventing sudden cardiac arrest, a life-threatening event that individuals with CHF may be susceptible to. The rapid delivery of an electric shock by defibrillators can restore normal heart rhythm, averting a potentially fatal outcome. Defibrillators are further classified into implantable cardioverter defibrillators and external cardioverter defibrillators.

   

• Implantable cardioverter defibrillators have evolved from single-chamber to dual-chamber to biventricular devices, offering more options and flexibility for CHF patients with different types and degrees of arrythmias. These devices are surgically implanted to continuously monitor heart rhythm. In the event of detected irregularities or dangerous arrhythmias, ICDs deliver precisely timed electric shocks to restore normal cardiac function.

   

• Moreover, defibrillators are extensively utilized in hospital settings, emergency departments, and cardiac care units. Their rapid deployment in these healthcare settings reinforces the segment's dominant market position, especially in acute care scenarios related to CHF complications.

The CHF treatment devices market by end-use is categorized into hospitals, cardiac clinics, ambulatory surgical centers, and other end-users. The hospitals segment accounted for around USD 10.5 billion revenue size in 2023.

• According to an article published by the National Library of Medicine, in 2021, Heart failure (HF) is one of the leading causes of hospital admission in the U.S. with over 1 million hospitalizations occurring annually, accounting for almost 6.5 million hospital days every year. Hospitals offer comprehensive cardiac care facilities equipped with state-of-the-art infrastructure, specialized healthcare professionals, and advanced medical technologies. This makes hospitals the primary setting for the diagnosis and management of CHF, including the deployment of treatment devices.

   

• Additionally, hospitals play a pivotal role in the implantation of various cardiac devices used in CHF management. This includes implantable cardioverter-defibrillators (ICDs), pacemakers, left ventricular assist devices (LVADs), and cardiac resynchronization therapy (CRT) devices. The expertise available in hospitals ensures the proper implantation and ongoing management of these devices. Therefore, the central role of hospitals in providing a comprehensive range of services across diverse specialties will fuel business growth positively.

North America congestive heart failure treatment devices market accounted for USD 10.3 billion revenue in 2023 and is predicted to witness substantial market growth over the analysis timeline.

• This notable market share can be attributed to various factors, including the presence of leading industry players, an increasing demand for cardiovascular devices, a rising incidence of cardiovascular conditions, and the growing number of hospital admissions throughout the country, among other key drivers.

   

• For instance, according to the Centers for Disease Prevention and Control (CDC) statistics, in 2020, cardiac disease was the leading cause of mortality in the U.S., accounting for around 697,000 deaths.

   

• Further, in the U.S., cardiac diseases have a heavy disease burden, costing approximately USD 229 billion every year from 2017 to 2018. Thus, the significant disease burden, high prevalence, & mortality rate are set to drive cardiac rhythm management devices market growth in the region.

   

• Furthermore, patients in the region are generally well-informed about healthcare options and often seek advanced and minimally invasive treatments. The growing demand from patients for effective and sophisticated solutions, such as congestive heart failure treatment devices, influences healthcare providers to offer these procedures.